← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
26	26 Vericel Corp VCEL $2.05B	261	+5	+2%	$2.32B
27	27 BridgeBio Pharma BBIO $12.9B	251	+7	+3%	$4.43B
28	28 Krystal Biotech KRYS $9.39B	245	+11	+5%	$5.24B
29	29 Veracyte VCYT $3.49B	240	-6	-2%	$1.78B
30	30 Editas Medicine EDIT $364M	236	+10	+4%	$263M
31	31 Pacific Biosciences PACB $541M	229	-39	-15%	$332M
32	32 Myriad Genetics MYGN $387M	223	+37	+20%	$2.25B
33	33 Beam Therapeutics BEAM $2.39B	214	-7	-3%	$1.82B
34	34 Maravai LifeSciences MRVI $1.02B	205	-5	-2%	$1.06B
35	35 PTC Therapeutics PTCT $4.93B	199	+15	+8%	$2.44B
36	36 Fate Therapeutics FATE $216M	182	+15	+9%	$401M
37	37 Legend Biotech LEGN $3.6B	181	-11	-6%	$4.06B
38	38 Regenxbio RGNX $457M	181	-7	-4%	$512M
39	39 Rocket Pharmaceuticals RCKT $245M	178	-8	-4%	$1.96B
40	40 Adaptive Biotechnologies ADPT $3.86B	177	-13	-7%	$539M
41	41 Allogene Therapeutics ALLO $449M	175	+14	+9%	$385M
42	42 Fulgent Genetics FLGT $546M	174	-6	-3%	$300M
43	43 DELISTED Arcellx ACLX	167	-16	-9%	$2.77B
44	44 DELISTED Verve Therapeutics VERV	167	+4	+2%	$372M
45	45 DELISTED BioLife Solutions BLFS	164	+15	+10%	$1B
46	46 OmniAb OABI $667M	160	+7	+5%	$294M
47	47 CareDx CDNA $3.3B	154	+7	+5%	$830M
48	48 DELISTED bluebird bio BLUE	150	-8	-5%	$78.4M
49	49 Sana Biotechnology SANA $686M	148	-6	-4%	$810M
50	50 DELISTED 23andMe Holding Co ME	147	-2	-1%	$39.3M